Thrombin Generation Testing for Monitoring Hemophilia Treatment: A Clinical Perspective

 

 Buy Article Permissions and Reprints

ABSTRACT

Thrombin generation is a key process that determines the extent of a hemostatic plug or a thrombotic process. The ensuing thrombin burst is crucial for the formation of a stable fibrin clot. During its active life, thrombin exerts a multitude of highly regulated actions on the blood and the vessel wall, among which is the clotting of fibrinogen. The inappropriate generation of thrombin may lead to pathological processes, foremost of which are hemorrhagic or thrombotic diseases. The coagulation system is usually investigated by means of two in vitro classical clotting tests, the activated partial thromboplastin time and prothrombin time. These assays assess only the time taken to form a clot and do not entirely reflect global hemostatic balance. They permit identification of connectivity between the component activities identified as required for plasma coagulation and define the concept of intrinsic and extrinsic coagulation pathways, which converge at the step of formation of the prothrombinase complex. However, the mechanisms established by in vitro tests are not always mirrored in the human pathologies associated with bleeding or thrombosis. The recent development of newer tests based on the continuous registration of thrombin generation (TG) under in vitro conditions that mimic more closely what occurs in vivo prompted us to reinvestigate the balance between procoagulants and anticoagulants in patients. Thrombin generation assays (TGA) not only provide an overall assessment of hemostasis, but they also target potential extrahemostatic effects of the generated thrombin, a potent agonist of a multitude of cellular activation pathways. Moreover, estimation of an individual's thrombin generation potential may correlate more closely with a hyper- or hypocoagulable phenotype, compared with traditional coagulation tests. In this review, we discuss to what extent TG can be expected to reflect the clotting function of blood, the development and use of different TGA systems suitable for detecting changes in the kinetics of thrombin generation, and the test's clinical utility for patients with hemophilia or von Willebrand disease.

REFERENCES

• 1 MacFarlane R G, Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia.  J Clin Pathol. 1953;  6(1) 3-8
  CrossrefPubMedGoogle Scholar
• 2 Pitney W R, Dacie J V. A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia.  J Clin Pathol. 1953;  6(1) 9-14
  CrossrefPubMedGoogle Scholar
• 3 Hemker H C, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential.  Thromb Haemost. 1995;  74(1) 134-138
  PubMedGoogle Scholar
• 4 Hemker H C, Giesen P, AlDieri R et al.. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability.  Pathophysiol Haemost Thromb. 2002;  32(5-6) 249-253
  CrossrefPubMedGoogle Scholar
• 5 Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment.  Haemophilia. 2008;  14(Suppl 3) 83-92
  CrossrefPubMedGoogle Scholar
• 6 Salvagno G L, Astermark J, Lippi G et al.. Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?.  Haemophilia. 2009;  15(1) 290-296
  CrossrefPubMedGoogle Scholar
• 7 Beltrán-Miranda C P, Khan A, Jaloma-Cruz A R, Laffan M A. Thrombin generation and phenotypic correlation in haemophilia A.  Haemophilia. 2005;  11(4) 326-334
  CrossrefPubMedGoogle Scholar
• 8 Jayandharan G R, Srivastava A. The phenotypic heterogeneity of severe hemophilia.  Semin Thromb Hemost. 2008;  34(1) 128-141
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Váradi K, Negrier C, Berntorp E et al.. Monitoring the bioavailability of FEIBA with a thrombin generation assay.  J Thromb Haemost. 2003;  1(11) 2374-2380
  CrossrefPubMedGoogle Scholar
• 10 Turecek P L, Váradi K, Keil B et al.. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay.  Pathophysiol Haemost Thromb. 2003;  33(1) 16-22
  CrossrefPubMedGoogle Scholar
• 11 Dargaud Y, Lambert T, Trossaert M. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors.  Haemophilia. 2008;  14(Suppl 4) 20-27
  PubMedGoogle Scholar
• 12 Terraube V, O'Donnell J S, Jenkins P V. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance.  Haemophilia. 2010;  16(1) 3-13
  PubMedGoogle Scholar
• 13 Hollestelle M J, Thinnes T, Crain K et al.. Tissue distribution of factor VIII gene expression in vivo—a closer look.  Thromb Haemost. 2001;  86(3) 855-861
  PubMedGoogle Scholar
• 14 Collins P W, Blanchette V S, Fischer K et al. rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A.  J Thromb Haemost. 2009;  7(3) 413-420
  CrossrefPubMedGoogle Scholar
• 15 Biggs R A, Douglas A S, MacFarlane R G, Dacie J V, Pitney W R, Merskey . Christmas disease: a condition previously mistaken for haemophilia.  BMJ. 1952;  2(4799) 1378-1382
  CrossrefPubMedGoogle Scholar
• 16 van den Berg H M, De Groot P H, Fischer K. Phenotypic heterogeneity in severe hemophilia.  J Thromb Haemost. 2007;  5(Suppl 1) 151-156
  CrossrefPubMedGoogle Scholar
• 17 Vicente V. Factor VIII half-life and intensity of treatment in hemophilic patients.  Haematologica. 2005;  90(4) 437
  PubMedGoogle Scholar
• 18 Franchini M, Montagnana M, Targher G et al.. Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia.  Semin Thromb Hemost. 2009;  35(3) 307-312
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Oldenburg J, Dolan G, Lemm G. Haemophilia care then, now and in the future.  Haemophilia. 2009;  15(Suppl 1) 2-7
  CrossrefPubMedGoogle Scholar
• 20 Dargaud Y, Negrier C. Thrombin generation testing in haemophilia comprehensive care centres.  Haemophilia. 2010;  16(2) 223-230
  CrossrefPubMedGoogle Scholar
• 21 Schwaab R, Oldenburg J, Kemball-Cook G et al.. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family.  Br J Haematol. 2000;  109(3) 523-528
  CrossrefPubMedGoogle Scholar
• 22 van Dijk K, van der Bom J G, Lenting P J et al.. Factor VIII half-life and clinical phenotype of severe hemophilia A.  Haematologica. 2005;  90(4) 494-498
  PubMedGoogle Scholar
• 23 Molho P, Rolland N, Lebrun T The French Study Group et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group.secretariat.haemophiles@cch.ap-hop-paris.fr.  Haemophilia. 2000;  6(1) 23-32
  CrossrefPubMedGoogle Scholar
• 24 Plug I, van der Bom J G, Peters M et al.. Thirty years of hemophilia treatment in the Netherlands, 1972–2001.  Blood. 2004;  104(12) 3494-3500
  CrossrefPubMedGoogle Scholar
• 25 Gilmore R, Harmon S, Gannon C, Byrne M, O'Donnell J S, Jenkins P V. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy.  Haemophilia. 2010;  16(4) 671-674
  PubMedGoogle Scholar
• 26 Berntorp E, Salvagno G L. Standardization and clinical utility of thrombin-generation assays.  Semin Thromb Hemost. 2008;  34(7) 670-682
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Bolton-Maggs P H, Pasi K J. Haemophilias A and B.  Lancet. 2003;  361(9371) 1801-1809
  CrossrefPubMedGoogle Scholar
• 28 Aledort L M, Haschmeyer R H, Pettersson H. The Orthopaedic Outcome Study Group . A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs.  J Intern Med. 1994;  236(4) 391-399
  CrossrefPubMedGoogle Scholar
• 29 Ljung R, Petrini P, Nilsson I M. Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases.  Acta Paediatr Scand. 1990;  79(2) 196-200
  PubMedGoogle Scholar
• 30 Nilsson I M, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.  J Intern Med. 1992;  232(1) 25-32
  CrossrefPubMedGoogle Scholar
• 31 Nichols W C, Amano K, Cacheris P M et al.. Moderation of hemophilia A phenotype by the factor V R506Q mutation.  Blood. 1996;  88(4) 1183-1187
  PubMedGoogle Scholar
• 32 Brummel-Ziedins K, Vossen C Y, Rosendaal F R, Umezaki K, Mann K G. The plasma hemostatic proteome: thrombin generation in healthy individuals.  J Thromb Haemost. 2005;  3(7) 1472-1481
  CrossrefPubMedGoogle Scholar
• 33 Nadeau J H. Modifier genes and protective alleles in humans and mice.  Curr Opin Genet Dev. 2003;  13(3) 290-295
  CrossrefPubMedGoogle Scholar
• 34 Ginsburg D. Identifying novel genetic determinants of haemostatic balance.  J Thromb Haemost. 2005;  3(8) 1561-1568
  CrossrefPubMedGoogle Scholar
• 35 Trossaërt M, Regnault V, Sigaud M, Boisseau P, Fressinaud E, Lecompte T. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype.  J Thromb Haemost. 2008;  6(3) 486-493
  CrossrefPubMedGoogle Scholar
• 36 Santagostino E, Mancuso M E, Tripodi A et al.. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile.  J Thromb Haemost. 2010;  8(4) 737-743
  CrossrefPubMedGoogle Scholar
• 37 Colvin B T, Astermark J, Fischer K Inter Disciplinary Working Group et al. European principles of haemophilia care.  Haemophilia. 2008;  14(2) 361-374
  CrossrefPubMedGoogle Scholar
• 38 Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment.  Haemophilia. 2008;  14(Suppl 3) 83-92
  CrossrefPubMedGoogle Scholar
• 39 van Veen J J, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet?.  Br J Haematol. 2008;  142(6) 889-903
  CrossrefPubMedGoogle Scholar
• 40 Dargaud Y, Béguin S, Lienhart A et al.. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.  Thromb Haemost. 2005;  93(3) 475-480
  PubMedGoogle Scholar
• 41 Berntorp E, Björkman S. The pharmacokinetics of clotting factor therapy.  Haemophilia. 2003;  9(4) 353-359
  CrossrefPubMedGoogle Scholar
• 42 Berntorp E. Factor VIII concentrates. In: Forbes CD, Aledort L Haemophilia. London, United Kingdom; Chapman & Hall 1997: 181-192
  Google Scholar
• 43 Barrowcliffe T W. Factor VIII and factor IX Sub-Committee. Recommendations for the assay of high-purity factor VIII concentrates.  Thromb Haemost. 1993;  70(5) 876-877
  PubMedGoogle Scholar
• 44 White GC 11, Shapiro A D, Kurczynski E M, Kim H C, Bergman G E. The Mononine Study Group . Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with haemophilia B.  Thromb Haemost. 1995;  73(5) 779-784
  PubMedGoogle Scholar
• 45 Dunn A L, Abshire T C. Current issues in prophylactic therapy for persons with hemophilia.  Acta Haematol. 2006;  115(3–4) 162-171
  CrossrefPubMedGoogle Scholar
• 46 Bolton-Maggs P H. Optimal haemophilia care versus the reality.  Br J Haematol. 2006;  132(6) 671-682
  CrossrefPubMedGoogle Scholar
• 47 Bassus S, Wegert W, Krause M et al.. Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.  Platelets. 2006;  17(6) 378-384
  CrossrefPubMedGoogle Scholar
• 48 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review.  Haemophilia. 2003;  9(4) 418-435
  CrossrefPubMedGoogle Scholar
• 49 Hall M. Haemophilia complicated by an acquired circulating anticoagulant: a report of three cases.  Br J Haematol. 1961;  7 340-348
  CrossrefPubMedGoogle Scholar
• 50 Berntorp E. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.  Haemophilia. 2007;  13(Suppl 5) 69-72
  CrossrefPubMedGoogle Scholar
• 51 White II G C, Rosendaal F, Aledort L M, Lusher J M, Rothschild C, Ingerslev J. Factor VIII and Factor IX Subcommittee . Definitions in hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.  Thromb Haemost. 2001;  85(3) 560
  Article in Thieme ConnectPubMedGoogle Scholar
• 52 Berntorp E, Shapiro A, Astermark J et al.. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference.  Haemophilia. 2006;  12(Suppl 6) 1-7
  PubMedGoogle Scholar
• 53 Astermark J, Oldenburg J, Escobar M, White II G C, Berntorp E. Malmö International Brother StudyGroup . The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.  Haematologica. 2005;  90(7) 924-931
  PubMedGoogle Scholar
• 54 Mannhalter C. The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.  Haematologica. 2005;  90(7) 869A
  PubMedGoogle Scholar
• 55 Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application.  Haemophilia. 2004;  10(Suppl 2) 10-16
  CrossrefPubMedGoogle Scholar
• 56 Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.  Haemophilia. 2009;  15(1) 3-10
  CrossrefPubMedGoogle Scholar
• 57 Turecek P L, Váradi K, Keil B et al.. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation assay.  Pathophysiol Haemost Thromb. 2003;  33(1) 16-22
  CrossrefPubMedGoogle Scholar
• 58 Váradi K, Negrier C, Berntorp E et al.. Monitoring the bioavailability of FEIBA with a thrombin generation assay.  J Thromb Haemost. 2003;  1(11) 2374-2380
  CrossrefPubMedGoogle Scholar
• 59 Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.  Haemophilia. 2008;  14(4) 782-786
  CrossrefPubMedGoogle Scholar
• 60 Dargaud Y, Lienhart A, Meunier S et al.. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.  Haemophilia. 2005;  11(5) 552-558
  CrossrefPubMedGoogle Scholar
• 61 Klintman J, Berntorp E, Astermark J. ON BEHALF OF THE MIBS STUDY GROUP* . Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.  Haemophilia. 2009;  , October 30 (Epub ahead of print)
  PubMedGoogle Scholar
• 62 Matsumoto T, Nogami K, Ogiwara K, Shima M. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A.  Int J Hematol. 2009;  90(5) 576-582
  CrossrefPubMedGoogle Scholar
• 63 Aljamali M N, Kjalke M, Hedner U, Ezban M, Tranholm M. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.  Haemophilia. 2009;  15(6) 1318-1326
  CrossrefPubMedGoogle Scholar
• 64 Brummel-Ziedins K E, Whelihan M F, Gissel M, Mann K G, Rivard G E. Thrombin generation and bleeding in haemophilia A.  Haemophilia. 2009;  15(5) 1118-1125
  CrossrefPubMedGoogle Scholar
• 65 Eichinger S, Lubsczyk B, Kollars M et al.. Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa.  Eur J Clin Invest. 2009;  39(8) 707-713
  CrossrefPubMedGoogle Scholar
• 66 Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.  Haemophilia. 2009;  15(4) 904-910
  CrossrefPubMedGoogle Scholar
• 67 Rosenthal R L, Dreskin O H, Rosenthal N. Plasma thromboplastin antecedent (PTA) deficiency; clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease.  Blood. 1955;  10(2) 120-131
  PubMedGoogle Scholar
• 68 Bolton-Maggs P H, Young Wan-Yin B, McCraw A H, Slack J, Kernoff P B. Inheritance and bleeding in factor XI deficiency.  Br J Haematol. 1988;  69(4) 521-528
  CrossrefPubMedGoogle Scholar
• 69 Bolton-Maggs P H. Factor XI deficiency—resolving the enigma?.  Hematology Am Soc Hematol Educ Program. 2009;  97-105
  PubMedGoogle Scholar
• 70 Seligsohn U. Factor XI deficiency in humans.  J Thromb Haemost. 2009;  7(Suppl 1) 84-87
  CrossrefPubMedGoogle Scholar
• 71 Furie B, Furie B C. Molecular basis of blood coagulation. In: Hoffman H, Benze EJ, Shattil SJ, et al Hematology, Basic Principles and Practice. 5th ed. Philadelphia, PA; Churchill Livingstone-Elsevier 2009: 1819-1836
  Google Scholar
• 72 Emsley J, McEwan P A, Gailani D. Structure and function of factor XI.  Blood. 2010;  115(13) 2569-2577
  CrossrefPubMedGoogle Scholar
• 73 Ghosh K, Mota L, Shetty S, Kulkarni B. Spectrum of changes in endogenous thrombin potential due to heritable disorders of coagulation.  Blood Coagul Fibrinolysis. 2008;  19(6) 577-580
  CrossrefPubMedGoogle Scholar
• 74 Mitka M. Guidelines for von Willebrand disease urge routine screening for bleeding.  JAMA. 2008;  299(16) 1890
  CrossrefPubMedGoogle Scholar
• 75 Terraube V, O'Donnell J S, Jenkins P V. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance.  Haemophilia. 2010;  16(1) 3-13
  PubMedGoogle Scholar
• 76 Mannucci P M. Treatment of von Willebrand's disease.  N Engl J Med. 2004;  351(7) 683-694
  CrossrefPubMedGoogle Scholar
• 77 Béguin S, Kumar R, Keularts I, Seligsohn U, Coller B S, Hemker H C. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor.  Blood. 1999;  93(2) 564-570
  PubMedGoogle Scholar
• 78 Rugeri L, Beguin S, Hemker C et al.. Thrombin-generating capacity in patients with von Willebrand's disease.  Haematologica. 2007;  92(12) 1639-1646
  CrossrefPubMedGoogle Scholar
• 79 Lippi G, Franchini M, Salvagno G L, Montagnana M, Poli G, Guidi G C. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.  J Thromb Thrombolysis. 2008;  26(2) 150-153
  CrossrefPubMedGoogle Scholar
• 80 Quiroga T, Goycoolea M, Giesen P L et al.. Thrombin generation in platelet-poor plasma is normal in patients with hereditary mucocutaneous haemorrhages.  Pathophysiol Haemost Thromb. 2003;  33(1) 30-35
  CrossrefPubMedGoogle Scholar
• 81 Keularts I M, Hamulyak K, Hemker H C, Béguin S. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients.  Thromb Haemost. 2000;  84(4) 638-642
  PubMedGoogle Scholar
• 82 Al Dieri R, Peyvandi F, Santagostino E et al.. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding.  Thromb Haemost. 2002;  88(4) 576-582
  PubMedGoogle Scholar
• 83 van Veen J J, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet?.  Br J Haematol. 2008;  142(6) 889-903
  CrossrefPubMedGoogle Scholar
• 84 Spaanderman M E, Van Beek E, Ekhart T H et al.. Changes in hemodynamic parameters and volume homeostasis with the menstrual cycle among women with a history of preeclampsia.  Am J Obstet Gynecol. 2000;  182(5) 1127-1134
  CrossrefPubMedGoogle Scholar
• 85 Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment.  Haemophilia. 2008;  14(Suppl 3) 83-92
  CrossrefPubMedGoogle Scholar
• 86 Dargaud Y, Luddington R, Gray E et al.. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study.  Br J Haematol. 2007;  139(2) 303-309
  CrossrefPubMedGoogle Scholar

Gian Luca SalvagnoM.D. 

Sezione di Chimica e Microscopia Clinica, Dipartimento di Scienze Morfologico-Biomediche, Università degl-i Studi di Verona

Ospedale Policlinico G.B. Rossi, Piazzale Scuro, 10, 37134 – Verona, Italy

Email: gsalvagno77@yahoo.it

Email: gianluca.salvagno@univr.it